OncoMed Pharmaceuticals has formed its second global alliance with a major pharmaceutical company in three years, this time with Bayer Schering Pharma for the discovery, development and commercialisation of novel anticancer stem cell therapeutics targeting the Wnt signalling pathway. The potential value of the deal to OncoMed is more than US$1 B, including US$40 M upfront.